Investigational drugs in recent clinical trials for treatment-resistant depression

Buprenorphine and the treatment of depression, anxiety, non-suicidal self-injury, and suicidality

(2016) L. Sher   ACTA PSYCHIATRICA SCANDINAVICA

Further Investigation of Ketamine

(2016) Robert Freedman   AMERICAN JOURNAL OF PSYCHIATRY

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

(2016) Jaskaran B. Singh et al.   AMERICAN JOURNAL OF PSYCHIATRY

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial

(2016) Maurizio Fava et al.   AMERICAN JOURNAL OF PSYCHIATRY

Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications

(2016) Melvyn W. Zhang et al.   BMC Medical Ethics

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

(2016) Raymond W. Lam et al.   BMC Psychiatry

Associations of low grade inflammation and endothelial dysfunction with depression – The Maastricht Study

(2016) Fleur E.P. van Dooren et al.   BRAIN BEHAVIOR AND IMMUNITY

The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant

(2016) Joseph Moskal et al.   Current Neuropharmacology

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder

(2016) Brittany Jaso et al.   Current Neuropharmacology

KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE

(2016) William V. Bobo et al.   DEPRESSION AND ANXIETY

Investigational drugs for treating agitation in persons with dementia

(2016) Ricardo P. Garay et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries

(2016) Ricardo P. Garay et al.   EXPERT OPINION ON PHARMACOTHERAPY

The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study

(2016) Cheng-Ta Li et al.   HUMAN BRAIN MAPPING

Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain

(2016) Wayne A. Ray et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants

(2016) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression

(2016) Bradley Gaynes   JOURNAL OF CLINICAL PSYCHIATRY

Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine

(2016) Dawn F. Ionescu et al.   JOURNAL OF CLINICAL PSYCHIATRY

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

(2016) James Lomas et al.   PHARMACOECONOMICS

Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders

(2016) Linda Nguyen et al.   PHARMACOLOGY & THERAPEUTICS

Quelle définition pour la dépression résistante ?

(2016) Jérôme Holtzmann et al.   PRESSE MEDICALE

La feuille de route des stratégies thérapeutiques de la dépression résistante

(2016) Wissam El-Hage   PRESSE MEDICALE

Dépression résistante : les autres stratégies thérapeutiques

(2016) Ghassen Saba et al.   PRESSE MEDICALE

Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression

(2016) Yong-Ku Kim et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity

(2016) K. Hashimoto   PSYCHOLOGICAL MEDICINE

Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial

(2016) Debbie Tallon et al.   Trials

Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression

(2016) Amany K. Hassan et al.   International Journal of Clinical Pharmacy

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study

(2015) George I. Papakostas et al.   AMERICAN JOURNAL OF PSYCHIATRY

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

(2015) D. Jeffrey Newport et al.   AMERICAN JOURNAL OF PSYCHIATRY

The promise of ketamine for treatment-resistant depression: current evidence and future directions

(2015) Kaitlin E. DeWilde et al.   Annals of the New York Academy of Sciences

Treatment-resistant Late-life Depression: Challenges and Perspectives

(2015) Christian Knochel et al.   Current Neuropharmacology

Potential serotonergic agents for the treatment of schizophrenia

(2015) Ricardo P. Garay et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?

(2015) Leslie Citrome et al.   Expert Review of Neurotherapeutics

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel

(2015) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia

(2015) Jeffrey L. Cummings et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants

(2015) Michael E. Thase et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder

(2015) Michael E. Thase et al.   JOURNAL OF CLINICAL PSYCHIATRY

Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent

(2015) SHELDON PRESKORN et al.   Journal of Psychiatric Practice

Is ketamine ready to be used clinically for the treatment of depression?

(2015) Colleen Loo   MEDICAL JOURNAL OF AUSTRALIA

Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial

(2015) Muhammad I. Husain et al.   Trials

Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization

(2015) Geng Tian et al.   Scientific Reports

The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?

(2015) Leslie Citrome et al.   Expert Review of Neurotherapeutics

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial

(2015) Olivia May Dean et al.   Clinical Psychopharmacology and Neuroscience

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

(2014) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

NMDA antagonists under investigation for the treatment of major depressive disorder

(2014) Bartłomiej Pochwat et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression

(2014) J. Craig Nelson et al.   JOURNAL OF AFFECTIVE DISORDERS

C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression

(2014) Patricia O. Chocano-Bedoya et al.   JOURNAL OF AFFECTIVE DISORDERS

Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults

(2014) Jordan F. Karp et al.   JOURNAL OF CLINICAL PSYCHIATRY

Review of Maintenance Trials for Major Depressive Disorder

(2014) Silvana Borges et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder

(2014) Elizabeth Brunner et al.   NEUROPSYCHOPHARMACOLOGY

Evaluation of Opioid Modulation in Major Depressive Disorder

(2014) Elliot Ehrich et al.   NEUROPSYCHOPHARMACOLOGY

Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan

(2014) Linda Nguyen et al.   PLoS One

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

(2014) A. McGirr et al.   PSYCHOLOGICAL MEDICINE

A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

(2014) Jeremy D. Coplan et al.   Frontiers in Behavioral Neuroscience

Association of Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in Young Adult Life

(2014) Golam M. Khandaker et al.   JAMA Psychiatry

Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects

(2014) Ole Köhler et al.   JAMA Psychiatry

New paradigms for treatment-resistant depression

(2013) Carlos Zarate et al.   Annals of the New York Academy of Sciences

Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies

(2013) Undine E. Lang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies

(2013) Vyara Valkanova et al.   JOURNAL OF AFFECTIVE DISORDERS

A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action

(2013) Marie Naughton et al.   JOURNAL OF AFFECTIVE DISORDERS

Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach

(2013) Roger S. McIntyre et al.   JOURNAL OF AFFECTIVE DISORDERS

Effects of S-Ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression

(2013) Kaija Järventausta et al.   JOURNAL OF ECT

Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial

(2013) Scott A. Irwin et al.   JOURNAL OF PALLIATIVE MEDICINE

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

(2013) G Sanacora et al.   MOLECULAR PSYCHIATRY

R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

(2013) Ji-chun Zhang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

(2012) James W. Murrough et al.   BIOLOGICAL PSYCHIATRY

Treatment-emergent adverse events associated with atypical antipsychotics

(2012) Danielle S Cha et al.   EXPERT OPINION ON PHARMACOTHERAPY

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

(2012) Lobna Ibrahim et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study

(2012) Tsuyoshi Miyaoka et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature

(2012) A. J. Ferrari et al.   PSYCHOLOGICAL MEDICINE

Treatment-resistant depression: therapeutic trends, challenges, and future directions

(2012) Al-harbi   Patient Preference and Adherence

Ketamine as a Novel Antidepressant: From Synapse to Behavior

(2011) J W Murrough   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug safety evaluation of ziprasidone

(2011) Leslie Citrome   Expert Opinion On Drug Safety

Treatment-Resistant Depression

(2011) Michael E. Thase   JOURNAL OF CLINICAL PSYCHIATRY

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

(2011) Adam L. Halberstadt et al.   NEUROPHARMACOLOGY

Towards a glutamate hypothesis of depression

(2011) Gerard Sanacora et al.   NEUROPHARMACOLOGY

Tocilizumab

(2010) Adith Venkiteshwaran   mAbs

Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

(2010) Leslie Citrome   POSTGRADUATE MEDICINE

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Stuck in a rut: rethinking depression and its treatment

(2010) Paul E. Holtzheimer et al.   TRENDS IN NEUROSCIENCES

RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)

(2009) Gregory M. Chandler et al.   CNS Neuroscience & Therapeutics

σ-1 receptors in major depression and anxiety

(2009) Shrinivas K Kulkarni et al.   Expert Review of Neurotherapeutics

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

(2009) Robert H. Howland   JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder

(2008) Richard C. Shelton et al.   ACTA PSYCHIATRICA SCANDINAVICA

Glutamate and the Neural Basis of the Subjective Effects of Ketamine

(2008) J. F. William Deakin et al.   ARCHIVES OF GENERAL PSYCHIATRY

Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders

(2007) Lewis L. Judd et al.   JOURNAL OF AFFECTIVE DISORDERS